Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Short-term Investments (2022 - 2025)

Indivior Pharmaceuticals has reported Short-term Investments over the past 4 years, most recently at $1.0 million for Q1 2025.

  • Quarterly results put Short-term Investments at $1.0 million for Q1 2025, changed N/A from a year ago — trailing twelve months through Mar 2025 was $1.0 million (changed N/A YoY), and the annual figure for FY2024 was $1.0 million, down 98.94%.
  • Short-term Investments for Q1 2025 was $1.0 million at Indivior Pharmaceuticals, roughly flat from $1.0 million in the prior quarter.
  • Over the last five years, Short-term Investments for INDV hit a ceiling of $119.0 million in Q4 2022 and a floor of $1.0 million in Q4 2024.
  • Median Short-term Investments over the past 4 years was $47.5 million (2023), compared with a mean of $53.8 million.
  • Biggest five-year swings in Short-term Investments: fell 21.01% in 2023 and later plummeted 98.94% in 2024.
  • Indivior Pharmaceuticals' Short-term Investments stood at $119.0 million in 2022, then decreased by 21.01% to $94.0 million in 2023, then plummeted by 98.94% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • The last three reported values for Short-term Investments were $1.0 million (Q1 2025), $1.0 million (Q4 2024), and $94.0 million (Q4 2023) per Business Quant data.